Amgen

Open: 219.67 Close: 222.1 Change: 2.43

What an AI can tell you about Amgen before investing.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, new, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Federal Trade Commission sues to block Amgen acquisition of Horizon Therapeutics. FTC is attempting to stop the sale out of fears it will give the company too much power. FTC has been taking a much more adversarial approach.

Today's News

Amgen Inc. (AMGN) latest stock news | seeking alpha. amgen inc. (amgn) latest press releases. amgen cuts 450 workers, cites drug pricing pressure and inflation. Amgen will delay buyout of horizon, complying with ftc request. Amgen will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on May 26, 2023. Federal Trade Commission sues to block Amgen acquisition of Horizon Therapeutics. FTC is attempting to stop the sale out of fears it will give the company too much power. Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately. Federal Trade Commission (FTC) has been taking a much more adversarial approach to mergers and acquisitions lately. Amgen presents new lumakras® (Sotorasib) codebreak 200 cns data at asco 2023. Amgens LUMAKRAS/LUMYKRAS, a KRAS G12C inhibitor, is progressing the largest and broadest global KRASG12C development program with unparalleled speed. Amgens LUMAKRAS/LUMYKRAS, a KRAS G12C inhibitor, is the leader in KRAS inhibition. Amgen continues to advance the CodeBreaK program. Amgen share price has underperformed the S&P500 Index by -15.73% over the past year. The overall consensus recommendation for Amgen is Hold. Amgen presents new lumakras® (sotorasib) codebreak 200 cns data at asco 2023. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. Amgen was awarded the Prix Galien for the invention of Lumakras, a new type of drug. In todays podcast, Im joined by Jonathan Graham, the executive vice president, general counsel, and secretary. Amgen presents new data from CodeBreaK clinical trial program at American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6. Amgen is progressing the largest and broadest global KRAS G12C  inhibitor development program with unparalleled speed. Amgen has submitted MAAs in Argentina, Colombia, Kuwait, Malaysia, Mexico, Russia, Saudi Arabia, Thailand and Turkey. Amgen reported an EPS of €3.711 in its last earnings report, beating expectations. Amgen recently announced new research evaluating the use of apremilast (Otezla) for the treatment of psoriatic arthritis. Amgen to present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET. Amgen: 221.84 (+1.73%) Pfizer and Seagen investors should be worried. Amgen presents new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting. More than 25 abstracts from Amgen-sponsored and collaborative studies will feature data in hard-to-treat tumor types. Amgen is currently investigating tarlatamab in multiple trials, including DeLLphi-301, a potentially registrational Phase 2 study in heavily pretreated SCLC. New data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C. Amgen presents new data from the CodeBreaK clinical trial program in patients with KRAS G12C-mutated cancers at the American Society of Clinical Oncologys annual meeting. LUMAKRAS shows improved PFS vs Docetaxel across key Co-Alteration Subgroups in the Phase 3 Code BreaK 200 Study. CodeBreaK clinical development program for sotorasib is designed to study patients with an advanced solid tumor with the KRAS  G12C-mutant. Amgen has several Phase 1b studies open for enrollment. Amgen announced the presentation of new CodeBreaK clinical trial data for its #KRASG12C inhibitor in patients with advanced non-small cell lung cancer. Amgen announced positive results in patients with active psoriatic arthritis in a new study that uses MRI to assess inflammation. Amgen underreported taxes by nearly $24 billion from 2010 to 2015, mainly by attributing what should have been United States taxable income to Puerto Rico unit.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, new, program, present, data, KRAS, CodeBreaK, and the most common words in the summary are: amgen, stock, market, news, price, new, top, . One of the sentences in the summary was: FTC has been taking a much more adversarial approach.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #market #news #price #new #top.